Literature DB >> 11439008

Asymptomatic carriage of Klebsiella pneumoniae producing extended-spectrum beta-lactamase by patients in a neurological early rehabilitation unit: management of an outbreak.

R Holländer1, M Ebke, H Barck, E von Pritzbuer.   

Abstract

During 11 months 58 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-Kp) isolates were grown from 10 patients on a neurological early rehabilitation unit. The patients had no signs of infection but were colonized in the nose and trachea, and unusually only one had colonization in the gut. A single clone of ESBL-Kp was identified by pulse field gel electrophoresis. Strong hygienic precautions similar to those for Methicillin-resistant Staphylococcus aureus patients prevented spread of the bacteria to other wards. However, rehabilitation for patients with severe neurological failures made it very difficult to follow hygienic requirements. Disinfection of mucous membranes was difficult. Eventually the application of a nasal spray containing povidone-iodine proved to be successful. Copyright 2001 The Hospital Infection Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439008     DOI: 10.1053/jhin.2001.0997

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  13 in total

1.  Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain.

Authors:  Aránzazu Valverde; Teresa M Coque; M Paz Sánchez-Moreno; Azucena Rollán; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in Korean community and hospital settings.

Authors:  Y J Ko; H-W Moon; M Hur; C-M Park; S E Cho; Y-M Yun
Journal:  Infection       Date:  2012-06-22       Impact factor: 3.553

3.  Healthcare-acquired infections in rehabilitation units of the Lombardy Region, Italy.

Authors:  M Tinelli; S Mannino; S Lucchi; A Piatti; L Pagani; R D'Angelo; M Villa; L Trezzi; M G Di Stefano; A Pavan; L Macchi
Journal:  Infection       Date:  2011-07-08       Impact factor: 3.553

Review 4.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

5.  High prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar.

Authors:  Todisoa Andriatahina; Frédérique Randrianirina; Eliosa Ratsima Hariniana; Antoine Talarmin; Honoré Raobijaona; Yves Buisson; Vincent Richard
Journal:  BMC Infect Dis       Date:  2010-07-12       Impact factor: 3.090

Review 6.  Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

Authors:  Mark E Rupp; Paul D Fey
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Persistence of nasal colonization with human pathogenic bacteria and associated antimicrobial resistance in the German general population.

Authors:  R Köck; P Werner; A W Friedrich; C Fegeler; K Becker
Journal:  New Microbes New Infect       Date:  2015-12-01

8.  Species-level analysis of DNA sequence data from the NIH Human Microbiome Project.

Authors:  Sean Conlan; Heidi H Kong; Julia A Segre
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

9.  Limits of patient isolation measures to control extended-spectrum beta-lactamase-producing Enterobacteriaceae: model-based analysis of clinical data in a pediatric ward.

Authors:  Matthieu Domenech de Cellès; Jean-Ralph Zahar; Véronique Abadie; Didier Guillemot
Journal:  BMC Infect Dis       Date:  2013-04-24       Impact factor: 3.090

10.  Fecal carriage of extended-spectrum β-lactamases and AmpC-producing Escherichia coli in a Libyan community.

Authors:  Salwa Fouad Ahmed; Mostafa Mohamed M Ali; Zienat Kamel Mohamed; Tarek A Moussa; John D Klena
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-06-16       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.